Which brand does the three shot COVID-19 vaccine belong to? Introduction to the main brands of COVID-19 vaccine

I believe that when you vaccinate COVID-19 vaccine, you will always find that COVID-19 vaccine has different needle types. Some of them are two shots, others are three shots, and even one shot has been launched to let more people get COVID-19 vaccine. What brand does the three shot COVID-19 vaccine belong to?

COVID-19 vaccine is a vaccine derived from continuous research. This vaccine can effectively prevent COVID-19, and to a certain extent, it can also enhance the resistance. Many friends are unfamiliar with various brands when getting vaccinated. Let's have a look at the brand of the three shot COVID-19 vaccine?

Zhifeilong Kema recombinant protein COVID-19 vaccine was jointly developed by Institute of Microbiology, Chinese Academy of Sciences and Anhui Zhifeilong Kema Biological Pharmaceutical Co., Ltd.

Recombinant protein vaccines are prepared by expressing and purifying pathogen antigen proteins in engineered cells through genetic engineering. Different from the adenovirus vector vaccine and inactivated vaccine previously approved for clinical trials, this is a COVID-19 vaccine developed by a new technical route. The vaccine was developed by the Gao Fu team and Yan Jinghua team from the Institute of Microbiology, Chinese Academy of Sciences. After the COVID-19 in 2020, Anhui Zhifeilong Kema took rapid action to start the research and development of COVID-19 vaccine by taking advantage of its own accumulation and advantages in the field of vaccine research and development for more than 10 years, becoming the only enterprise in Anhui Province to research and develop COVID-19 vaccine, and obtaining the support of the Ministry of Science and Technology's key special project "public security risk prevention and control and emergency technical equipment". The vaccine was approved for clinical trials by the National Medical Products Administration on June 19 last year; On June 22nd and July 10th, phase I and II clinical trials were conducted successively; The Phase III clinical trials, both domestically and internationally, were launched on November 18th in Xiangtan County, Hunan Province, China, and on December 10th in Tashkent, the capital of Uzbekistan, and are progressing smoothly.

The results showed that there was no serious adverse reaction after the whole vaccination, which was consistent with the characteristics of low adverse reaction of subunit vaccine, and the neutralizing antibody level produced was equivalent to the current international recombinant protein vaccine and mRNA COVID-19 vaccine.

It is reported that due to the use of engineered cells to produce recombinant proteins in vaccine production, there is no need for high-level biosafety laboratory production workshops. The technology is advanced and mature, the production process is stable and reliable, the safety is good, the quality is controllable, and there are no biosafety risks in vaccine production. It is easy to scale up production, significantly reducing vaccine production costs, and storage and transportation are convenient.

In fact, the three shot COVID-19 vaccine is also a very good vaccine. It needs to be noted when vaccinating. There will be certain restrictions on the vaccination time. If you do not vaccinate within the specified time, you may not achieve better results. This must be paid special attention.